• Disclosure
  • Privacy Policy
  • DMCA Policy
  • CCPA
  • Medical Disclaimer
Monday, January 30, 2023
Massachusetts Digital News
  • Home
  • US
  • Business
  • World
  • Boston
  • Worcester
  • Springfield
  • Cambridge
  • Lowell
  • Brockton
  • Press Releases
  • Videos
No Result
View All Result
  • Home
  • US
  • Business
  • World
  • Boston
  • Worcester
  • Springfield
  • Cambridge
  • Lowell
  • Brockton
  • Press Releases
  • Videos
No Result
View All Result
No Result
View All Result
Home Cambridge

Lilly Breaks The Bank On The Potential For RNA With $700M Investment In Boston

by Duong
February 22, 2022
in Cambridge
lilly-breaks-the-bank-on-the-potential-for-rna-with-$700m-investment-in-boston
Share on FacebookShare on Twitter

Franz Hefti Prevail tile scaled

Franz Hefti, co-director of the Lilly Institute for Generic Medicine and CEO of Lilly sub Prevail

February 22, 2022 09:16 AM EST

Lilly breaks the bank on the potential for RNA with $700M investment in Boston’s Seaport

Kyle Blankenship

Managing Editor

In the latest boom across drug R&D, Big Pharma has dumped billions into research for RNA-based therapies, betting big on the future in that space. Now, Eli Lilly wants an even bigger piece of the action and will plant its flag in Boston to help pave the way.

Lilly will dole out $700 million for a new research site at Boston’s Seaport district as part of the company’s broader push into RNA medicines, the Indianapolis-based drugmaker said Monday.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 133,700+ biopharma pros reading Endpoints daily — and it’s free.

Endpoint New article 1800x800 d02 2 1 1

SPONSORED

February 21, 2022 06:00 AM EST

Centralize Clinical Trials with Decentralized Clinical Trials

David Coman

Chief Executive Officer

With agile and decentralized approaches, sponsors actually have more centralized command and oversight.

One of the most notable early uses of the term “decentralized clinical trials” came from the presiding FDA Commissioner, Dr. Scott Gottlieb, in a January 2019 speech, where he noted that decentralization can, “help clinical trials become agile and efficient by reducing the administrative burdens on sponsors and those conducting trials, and can allow patients to receive treatments from community providers without compromising the quality of the trial or the integrity of the data being collected,”¹

AI hype fi

February 22, 2022 07:48 AM EST

Biopharma has hyped AI for years. But as the first trials get underway, experts try to manage expectations

If you’re at all familiar with the biotech space, you’ve probably heard of the promises of artificial intelligence and machine learning.

These promises have been tantalizing. AI and ML can, proponents claim, help researchers speed along the arduous and expensive drug development process. By attempting to utilize algorithms and computing power so dynamic as to essentially eliminate menial tasks and trial and error altogether, the technology comes with big expectations likening it to a new industrial revolution.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

February 22, 2022 07:17 AM ESTUpdated 08:01 AM

Homology joins BioMarin in halting gene therapy studies for rare metabolic disease

It was a tough week for companies, patients and families hoping a gene therapy for the rare metabolic disease phenylketonuria is on its way.

On Friday afternoon, after BioMarin had already announced its program would be on hold for at least “several quarters,” Homology Medicines disclosed that the FDA had also halted trials for its phenylketonuria gene therapy.

The timing partly reflects the greater scrutiny gene therapy has come under at the FDA over the last year. But despite similarities between the two programs, the agency’s concerns appear to be unrelated, reflecting distinct safety concerns with the technology.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 133,700+ biopharma pros reading Endpoints daily — and it’s free.

Susan Galbraith scaled

Susan Galbraith, AstraZeneca EVP, oncology R&D

February 22, 2022 07:11 AM EST

Claiming historic first, AstraZeneca says Enhertu aces PhIII for hard-to-reach segment of patients

AstraZeneca has racked up a crucial Phase III win for its megablockbuster prospect Enhertu — one that could push the drug to unchartered places currently unreachable for its peers.

For a while now, the pharma giant has been talking about how its third-gen antibody drug conjugate, developed in a $6.9 billion partnership with Daiichi Sankyo, could do a better job going after tumors marked by various levels of HER2 expression — even those that would traditionally be described as “HER2-low.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 133,700+ biopharma pros reading Endpoints daily — and it’s free.

Richard Marsden scaled

Richard Marsden, Synairgen CEO

February 22, 2022 07:26 AM EST

Biotech shares eviscerated in wake of Covid-19 flop

When Southampton, UK-based Synairgen last updated its investors, CEO Richard Marsden spotlighted the progress it’s making on the Phase III SPRINTER trial for the lead candidate, SNG001, an inhaled interferon beta formulation, for patients hospitalized for Covid-19. The biotech was building the infrastructure to prepare for an EUA in the US and subsequent approvals around the world, and positive data from the trial, it added, would “represent a major breakthrough in the battle against Covid-19.”

Tillman Gerngross Getty tile scaled

Tillman Gerngross (Craig F. Walker/The Boston Globe via Getty Images)

February 22, 2022 07:08 AM EST

After raising more than $750M in quick Covid cash, Tillman Gerngross is on his way out of troubled Adagio

John Carroll

Editor & Founder

The renowned antibody expert Tillman Gerngross founded Adagio in the frantic early days of the pandemic with a mission to come up with a groundbreaking antibody to fight Covid-19. The first $50 million was committed within 24 hours of his first calls. His biotech went public last summer at $17 a share — after raising $470 million from the VCs — in the middle of a biotech boom and quickly more than tripled in value, spiking in a second big wave as Omicron stoked fresh fears of a tsunami of cases.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 133,700+ biopharma pros reading Endpoints daily — and it’s free.

Ugur Sahin AP BioNTech tile scaled

Uğur Şahin, BioNTech CEO (AP Images)

February 22, 2022 07:13 AM EST

BioNTech signs immunotherapy deal with Medigene as post-Covid strategy takes shape

Continuing to chart its path forward post-pandemic, BioNTech struck a new deal Monday aimed at boosting its presence in oncology.

The Covid-19 vaccine maker signed a collaboration with Germany’s Medigene, the companies announced, giving BioNTech the rights to a preclinical T cell receptor (TCR) program and licenses to other Medigene technologies. In return, Medigene received about $29.5 million in upfront cash and will be eligible for milestones described only as “payments up to a triple digit million EUR amount per program.”

February 19, 2022 06:00 AM EST

Inside PBMs’ tactics to tilt the market; Is the KRAS race still on? CAR-T safety scares trigger halts; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

We are, thankfully, headed into a three-day weekend here at Endpoints News. For those of you who follow the daily reports, see you on Tuesday. Otherwise, enjoy the rest and this report will hit your inbox again next Saturday.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 133,700+ biopharma pros reading Endpoints daily — and it’s free.

February 18, 2022 02:28 PM ESTUpdated 03:15 PM

When the $10K brand name drug is more affordable than its $450 generic: How PBMs control the system

Zachary Brennan

Senior Editor

Pharmacy benefit managers — the much-maligned middlemen between drug manufacturers and health insurers — often tilt the market, 80% of which is controlled by 3 of the largest PBMs, in their own and unusual ways.

These games, like clawing back money after a prescription has been dispensed, or offering reimbursements that don’t cover the cost of what pharmacies pay for a drug, were on full display at Thursday’s meeting where the Federal Trade Commission debated whether to look into these PBMs, some of which have grown so big to be on the Fortune 15.

Read More Here

Related Posts

head-to-head-survey:-voyager-therapeutics-(nasdaq:vygr)-&-surface-oncology-(nasdaq:surf)

Head-To-Head Survey: Voyager Therapeutics (NASDAQ:VYGR) & Surface Oncology (NASDAQ:SURF)

by Duong
April 14, 2022
0

Posted by admin on Apr 14th, 2022 Voyager Therapeutics (NASDAQ:VYGR – Get Rating) and Surface Oncology (NASDAQ:SURF – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, valuation, analyst recommendations, risk...

energy-workshop-–-announcements-–-e-flux

Energy Workshop – Announcements – E-Flux

by Duong
April 13, 2022
0

The first edition of the Norman Foster Foundation’s Energy Workshop will take place from April 25–29, 2022 with the support of GS Energy. “With energy, we stand on the shoulders of giants with our heads in the clouds,” states the workshop’s Mentor, Luke Olsen. As he puts it, “we need to...

men’s-and-women’s-tennis-complete-successful-weekend-with-wins-over-columbia,-cornell-|-sports-|-the-harvard-crimson

Men’s And Women’s Tennis Complete Successful Weekend With Wins Over Columbia, Cornell | Sports | The Harvard Crimson

by NewsReporter
April 12, 2022
0

“One thing that our team has really come a long way in this semester is with our confidence and belief in ourselves,” said first-year Holly Fischer. “So I think that even though we were down, everyone who was playing was fighting so hard and really leaving everything out on the...

artist-pritika-chowdhry’s-‘anti-memorials’-illustrate-what-is-excluded-from-collective-memories-of-partition

Artist Pritika Chowdhry’s ‘anti-Memorials’ Illustrate What Is Excluded From Collective Memories Of Partition

by Duong
April 11, 2022
0

The Jallianwala Bagh Massacre is one of the most significant events in the history of the sub-continent. Many people, including women and children, lost their lives on April 13, 1919, the day of Baisakhi when General Reginald Edward Dy ordered soldiers to open fire on the gathering — camping in...

Massachusetts Digital News

© 2021 Massachusetts Digital News

Navigate Site

  • Disclosure
  • Privacy Policy
  • DMCA Policy
  • CCPA
  • Medical Disclaimer

Follow Us

No Result
View All Result
  • Home
  • DMCA Policy
  • Medical Disclaimer
  • Privacy Policy
  • Disclosure
  • CCPA
  • Terms of Use

© 2021 Massachusetts Digital News

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT